NBJ REPORT: Supplements in the Ozempic Age - Available for Presale

A deep dive into supplement industry opportunities in and around GLP-1 drugs

If you are having trouble reading this email, read the online version Are you ready to capitalize on the rapid rise of GLP-1 drugs like Ozempic in the weight loss and blood sugar management markets? NBJ's special report Supplements in the Ozempic Age provides comprehensive market insights and extensive GLP-1 consumer survey data, and it's available for presale. This report features 67 consumer survey charts covering the full spectrum of consumers that are considering, currently taking, or have previously taken GLP-1 drugs to address weight-related concerns. These surveys provide valuable insights into how consumers perceive the role of supplements in weight loss and blood sugar management, both as standalone solutions and in conjunction with GLP-1 drugs like Ozempic. Want more details about Supplements in the Ozempic Age or an early preview? Let’s schedule a call to discuss how this report can help you unlock new growth opportunities. Get in Touch Related Reports Sports Nutrition and Weight Management Supplement Business Report Interested in more information? Connect with us here. This email was sent to you by the Informa Markets Division of Informa PLC (Privacy Policy). Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. If you do not wish to receive further information from us, please click here. Alternatively, to contact our data services team to have your details or preferences updated please email imdatateam@informa.com.